Supplemental NDA (sNDA)

Also known as: sNDA, supplemental new drug application, label expansion, efficacy supplement

A supplemental New Drug Application (sNDA) is a request to the FDA to change the terms of an already approved NDA. The most market-relevant type is the efficacy supplement, used to add a new indication or expand the approved patient population. The equivalent for biologics is a supplemental BLA (sBLA).

How it works

Supplements cover many kinds of changes: new indications, new dosing regimens, new formulations or strengths, labeling updates and manufacturing changes. Efficacy supplements typically require new clinical data, often a Phase 3 trial in the new population.

Under PDUFA, efficacy supplements have review goals of 10 months for standard review and 6 months for priority review, measured from receipt. As with an original application, the result is an approval or a complete response letter. Many routine manufacturing and labeling supplements are minor and never make news.

Why it matters for traders

For commercial-stage drugmakers, label expansions are how a drug's sales keep growing after launch. An sNDA approval for a large new indication, such as moving a cancer drug into an earlier line of therapy, can materially lift revenue forecasts. Things traders watch:

  • Size of the new population relative to the current label.
  • The PDUFA date for the supplement, disclosed by the company.
  • Label wording. A narrower-than-expected indication can disappoint even on approval.

Example

Northwind Therapeutics (NWTX) markets a drug approved for adults with a rare liver disease, a market of about 20,000 US patients. It files an sNDA to add a second, related condition affecting about 30,000 patients, with standard review. If approved, the addressable population rises 150% to roughly 50,000.

FAQ

What is the difference between an NDA and an sNDA?

An NDA seeks the first approval of a drug. An sNDA seeks to change an existing approval, for example to add a new use.

Does an sNDA need new trials?

Efficacy supplements for new indications usually do. Manufacturing or labeling supplements often do not.

Track it on Quantisnow

Related terms

Part of the Quantisnow financial glossary. For longer explainers, see the investing guides. Educational content, not investment advice.